What is claimed is:

~~1. A method~~1. Use of an interleukin-4 receptor (IL-4R) antagonist for the manufacture of a medicament for enhancing the efficacy, safety, and/or tolerability of a peanut allergen immunotherapy regimen in a subject having a peanut allergy, ~~the method comprising administering to the subject~~wherein one or more doses of ~~an interleukin-4 receptor (~~the IL-4R~~)~~ antagonist is to be administered to the subject in combination with the immunotherapy regimen, wherein at least one dose of the IL-4R antagonist is to be administered prior to the start of the immunotherapy regimen, and wherein the IL-4R antagonist is an anti-IL-4R antibody, or an antigen-binding fragment thereof, that comprises the heavy chain complementarity determining regions (HCDRs) of a heavy chain variable region (HCVR) comprising the amino acid sequence of SEQ ID NO:1 and the light chain complementarity determining regions (LCDRs) of a light chain variable region (LCVR) comprising the amino acid sequence of SEQ ID NO:2.

2. The ~~method~~use of claim 1, wherein the immunotherapy regimen is an oral immunotherapy (OIT) regimen.

3. The ~~method~~use of claim 1 or 2, wherein the peanut allergen is a composition comprising peanut flour.

4. The ~~method~~use of any one of claims 1 to 3, wherein the immunotherapy regimen comprises an up-dosing phase followed by a maintenance phase, wherein the up-dosing phase comprises ~~administering~~ increasing doses of the peanut allergen to be administered over a period of at least 24 weeks and wherein the maintenance phase comprises ~~administering~~ one or more maintenance doses of the peanut allergen to be administered at the highest dose ~~administered~~ during the up-dosing phase.

5. The ~~method~~use of claim 4, wherein the up-dosing phase comprises an initial dose escalation day (IDED) regimen followed by increasing dose escalations every two weeks.

6 .The ~~method~~use of claim 4 or 5, wherein the up-dosing phase comprises up-dosing from an initial dose of 0.5 mg peanut protein to a dose of 300 mg peanut protein and wherein the maintenance phase comprises ~~administering~~ one or more maintenance doses of 300 mg peanut protein to be administered.

7. The ~~method~~use of any one of claims 1 to 6, wherein the subject is aged ≥ 6 years old to < 18 years old.

8. The ~~method~~use of any one of claims 1 to 7, wherein the subject has one or more of the following baseline characteristics:

(a) a clinical history of allergy to peanuts or peanut-containing foods;

(b) experiences dose-limiting symptoms at or before a challenge dose of 100 mg peanut protein, or at a cumulative dose of ≤144 mg of peanut protein, in a double-blind, placebo-controlled food challenge (DBPCFC);

(c) has a serum IgE to peanut of ≥10 kUA/L; or

(d) has a skin prick test (SPT) to peanut ≥8 mm.

9. The ~~method~~use of any one of claims 1 to 8, wherein the subject has concomitant atopic dermatitis, asthma, eosinophilic esophagitis, and/or multiple food allergies.

10. The ~~method~~use of any one of claims 1 to 9, wherein the IL-4R antagonist is to be administered at a dose of about 50 mg to about 600 mg.

11. The ~~method~~use of any one of claims 1 to 10, wherein the IL-4R antagonist is to be administered as an initial dose followed by one or more secondary doses, wherein each secondary dose is to be administered 1 to 4 weeks after the immediately preceding dose.

12. The ~~method~~use of claim 11, wherein each secondary dose of the IL-4R antagonist is to be administered two weeks after the immediately preceding dose.

13. The ~~method~~use of any one of claims 1 to 12, wherein the IL-4R antagonist is to be administered subcutaneously or intravenously.

14. The ~~method~~use of any one of claims 1 to 11, wherein the IL-4R antagonist is to be subcutaneously administered at an initial dose followed by one or more secondary doses, wherein each secondary dose is to be administered 1 to 4 weeks after the immediately preceding dose, and wherein:

(i) for a subject weighing <30 kg, the initial dose of the IL-4R antagonist is 200 mg and each secondary dose is 100 mg; or

(ii) for a subject having a body weight of ≥30 kg to <60 kg, the initial dose of the IL-4R antagonist is 400 mg and each secondary dose is 200 mg; or

(iii) for a subject having a body weight of ≥60 kg, the initial dose of the IL-4R antagonist is 600 mg and each secondary dose is 300 mg.

15. The ~~method~~use of claim 14, wherein the subject has a body weight of <30 kg and the IL-4R antagonist is to be administered at an initial dose of 200 mg followed by one or more secondary doses of 100 mg every two weeks (Q2W).

16. The ~~method~~use of claim 14, wherein the subject has a body weight of ≥30 kg to <60 mg and the IL-4R antagonist is to be administered at an initial dose of 400 mg followed by one or more secondary doses of 200 mg every two weeks (Q2W).

17. The ~~method~~use of claim 14, wherein the subject has a body weight of ≥60 mg and the IL-4R antagonist is to be administered at an initial dose of 600 mg followed by one or more secondary doses of 300 mg every two weeks (Q2W).

18. The ~~method~~use of any one of claims 11 to 17, wherein the initial dose of the IL-4R antagonist is to be administered at least two weeks before the start of the immunotherapy regimen.

19. The ~~method~~use of claim 18, wherein the IL-4R antagonist is to be administered for at least four weeks before the start of the immunotherapy regimen.

20. The ~~method~~use of any one of claims 1 to 19, wherein ~~administration of~~ the IL-4R antagonist to be administered:

(i) increases the cumulative tolerated dose of peanut protein as measured by a DBPCFC; and/or

(ii) decreases the frequency and/or severity of peanut allergic symptoms, gastrointestinal symptoms, and/or itching symptoms.

21. The ~~method~~use of any one of claims 1 to 20, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises three HCDRs (HCDR1, HCDR2 and HCDR3) and three LCDRs (LCDR1, LCDR2 and LCDR3), wherein the HCDR1 comprises the amino acid sequence of SEQ ID NO:3; the HCDR2 comprises the amino acid sequence of SEQ ID NO:4; the HCDR3 comprises the amino acid sequence of SEQ ID NO:5; the LCDR1 comprises the amino acid sequence of SEQ ID NO:6; the LCDR2 comprises the amino acid sequence of SEQ ID NO:7; and the LCDR3 comprises the amino acid sequence of SEQ ID NO:8.

22. The ~~method~~use of any one of claims 1 to 21, wherein the anti-IL-4R antibody or antigen-binding fragment thereof comprises a HCVR comprising the amino acid sequence of SEQ ID NO:1 and comprises a LCVR comprising the amino acid sequence of SEQ ID NO:2.

23. The ~~method~~use of any one of claims 1 to 22, wherein the anti-IL-4R antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:9 and a light chain comprising the amino acid sequence of SEQ ID NO:10.

24. The ~~method~~use of any one of claims 1 to 23, wherein the IL-4R antagonist is dupilumab.

25. The ~~method~~use of any one of claims 1 to 24, wherein the IL-4R antagonist is contained in a container selected from the group consisting of a glass vial, a syringe, a pre-filled syringe, a pen delivery device, and an autoinjector.

26. The ~~method~~use of claim 25, wherein the IL-4R antagonist is contained in a pre-filled syringe.

27. The ~~method~~use of claim 26, wherein the pre-filled syringe is a single-dose pre-filled syringe.

28. The ~~method~~use of claim 25, wherein the IL-4R antagonist is contained in an autoinjector.

29. The ~~method~~use of claim 25, wherein the IL-4R antagonist is contained in a pen delivery device.